NEW

Veterinary Use

No itching, no pruritus,
no stress, no effort

Xintópica®

Oclacitinib maleate



SUPER CHEWS ™ DELICIOUS FLAVOR

Soft Chews
Chewable Soft Tablets

petmedica®



Xintópica® Soft Chews

Oclacitinib maleate

1.5 mg | 3 mg | 6 mg | 12 mg



CONTROL OF ATOPIC DERMATITIS AND SUSTAINED RELIEF OF PRURITUS ASSOCIATED WITH ALLERGIC DERMATITIS IN DOGS

Xintópica® Soft Chews is indicated for the treatment of acute or chronic canine pruritus associated with allergic dermatitis (FAD), atopic dermatitis, and sarcoptic mange.

Xintópica® allows for the continuation of the investigation into the underlying cause, allergy testing and serological tests.

NO SIDE EFFECTS ASSOCIATED WITH CORTICOSTEROID USE

Oclacitinib is considered a better option compared to corticosteroids (such as prednisone or dexamethasone), which cause broader and more generalized immunosuppressive effects, making their long-term use unsustainable.


FAST-ACTING RELIEF

Xintópica® Soft Chews controls pruritus in less than 4 hours, providing rapid, effective, and safe relief. Field reports demonstrate the product's effectiveness, significantly reducing pruritus and the severity of canine allergic dermatitis in just one week.

(*) Krklec S, Lescano A, Torres V. 2024. Effectiveness of using a chewable oclacitinib-based tablet for the control of pruritus in canines with allergic dermatitis.

MECHANISM OF ACTION OF OCLACITINIB

Xintópica® Soft Chews contains oclacitinib, a Janus kinase (JAK) inhibitor that interferes with the JAK-STAT signaling pathway. It selectively inhibits proinflammatory cytokines, relieving allergic, pruritic, and inflammatory symptoms with minimal impact on the immune system. Specifically, oclacitinib inhibits IL-31, a key pruritogenic cytokine in atopic dogs, as well as proinflammatory cytokines such as IL-2, IL-4, IL-6, and IL-13, which also play important roles in canine atopic dermatitis.



BREAK THE ITCH-SCRATCH CYCLE AND RESTORE YOUR PATIENTS' QUALITY LIFE WITH XINTÓPICA®



HIGHLY PALATABLE

Great taste drives treatment adherence and therapeutic success in your patient. Xintópica® Soft Chews are designed for voluntary and enjoyable intake, with no need to force administration.

- SOFT TEXTURE
- PLEASANT SMELL AND FLAVOR
- HIGH ACCEPTANCE
- COMPLETE DISINTEGRATION
- PRACTICAL AND VERSATILE



Xintópica® Soft Chews

Oclacitinib maleate

RECOMMENDED DOSES

Administered orally at a dosage of 0.4 – 0.6 mg/kg every 12 hours for up to 14 days, then 0.4 – 0.6 mg/kg every 24 hours as maintenance therapy.

Available in 4 presentations of 32 chewable soft tablets. You can use the tablet cutter provided inside the Xintópica® box to deliver an exact dose according to the dog's weight.

	1.5 mg	3 mg	6 mg	12 mg
2.5 to 3.7 kg				
3.8 to 4.9 kg				
5 to 7.5 kg				
7.6 to 10.5 kg				
10.6 to 15 kg				
15.1 to 20 kg				
20.1 to 30 kg				
30.1 to 45 kg				
45.1 to 60 kg				
Diameter	11.3 - 13 mm	14 - 16.29 mm	11.3 - 13 mm	14 - 16.29 mm





CAN BE USED IN DOGS FROM 12 MONTHS OF AGE AND 2.5 KG IN WEIGHT.

Sample materials, packaging, whether digital or printed, are provided by Agrovet Market or its representatives for informational purposes only. The content is global and general in nature and shall not, under any circumstances, be construed as an attempt to undermine, infringe, or challenge the validity of any registration, patent, or intellectual property right in the country where this information is distributed or received.

petmedica®

For more information:
sales@agrovetmarket.com
511 2 300 300 / (+51) 922 926 786
www.agrovetmarket.com
Av. Canadá 3792 - 3798
San Luis, 15021 - Lima - Perú

TÜVRheinland CERTIFIED
Management System
ISO 9001:2015
ISO 27001:2013
www.tuv.com
ID 9105063844